Jeffrey Bienstock, MD, FAAP, identifies the various triggers causing flare-ups for atopic dermatitis in patients.

The role of multidisciplinary management in diagnosing atopic dermatitis and when patients typically seek care.

Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, discuss whether children outgrow atopic dermatitis and advice for the management of disease.

Elizabeth Swanson, MD, leads the discussion on emerging data on comorbid conditions associated with atopic dermatitis and management in the clinical setting.

Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, discuss the importance of an integrative approach to care for the management of atopic dermatitis.

Reviewing the importance of newer models of collaboration between specialty and primary care for atopic dermatitis and educating patients and caregivers for disease management.

Patient factors considered when prescribing treatment options for the management of atopic dermatitis.

Peter Lio, MD, and Elizabeth Swanson, MD, provide insight on using nonpharmacological therapies and state-of-the-art skin care treatments for patients with atopic dermatitis.

Experts in the management of atopic dermatitis review the safety and efficacy of topical calcineurin inhibitors and topical PDE4 inhibitors.

A review of the safety and efficacy of systemic agents such as methotrexate, azathioprine, and cyclosporine in patients with severe, persistent atopic dermatitis.

Examining the potential role for biologic, dupilumab, in the treatment of moderate to severe atopic dermatitis.

A discussion on ease of access for dupilumab for the treatment of atopic dermatitis including the process for approval and coverage.

Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, review additional mechanisms being investigated in the pipeline for the treatment of atopic dermatitis.